|
1
|
Ricard D, Idbaih A, Ducray F, Lahutte M,
Hoang-Xuan K and Delattre JY: Primary brain tumours in adults.
Lancet. 379:1984–1996. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hess KR, Broglio KR and Bondy ML: Adult
glioma incidence trends in the United States, 1977–2000. Cancer.
101:2293–2299. 2004.PubMed/NCBI
|
|
3
|
Johannesen TB, Langmark F and Lote K:
Cause of death and long-term survival in patients with
neuro-epithelial brain tumours: a population-based study. Eur J
Cancer. 39:2355–2363. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang Y, Chao T, Li R, Liu W, Chen Y, Yan
X, Gong Y, Yin B, Liu W, Qiang B, Zhao J, Yuan J and Peng X:
MicroRNA-128 inhibits glioma cells proliferation by targeting
transcription factor E2F3a. J Mol Med (Berl). 87:43–51. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Komotar RJ, Otten ML, Moise G and Connolly
ES Jr: Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma-a critical review. Clin Med Oncol. 2:421–422.
2008.PubMed/NCBI
|
|
6
|
Stummer W and Kamp MA: The importance of
surgical resection in malignant glioma. Curr Opin Neurol.
22:645–649. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A,
Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO:
Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glinsky GV: Death-from-cancer signatures
and stem cell contribution to metastatic cancer. Cell Cycle.
4:1171–1175. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang XY, Varthi M, Sykes SM, Phillips C,
Warzecha C, Zhu W, Wyce A, Thorne AW, Berger SL and McMahon SB: The
putative cancer stem cell marker USP22 is a subunit of the human
SAGA complex required for activated transcription and cell-cycle
progression. Mol Cell. 29:102–111. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li J, Wang Z and Li Y: USP22 nuclear
expression is significantly associated with progression and
unfavorable clinical outcome in human esophageal squamous cell
carcinoma. J Cancer Res Clin Oncol. 138:1291–1297. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yang DD, Cui BB, Sun LY, Zheng HQ, Huang
Q, Tong JX and Zhang QF: The co-expression of USP22 and BMI-1 may
promote cancer progression and predict therapy failure in gastric
carcinoma. Cell Biochem Biophys. 61:703–710. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu Y, Yang Y, Xu H and Dong X:
Implication of USP22 in the regulation of BMI-1, c-Myc, p16INK4a,
p14ARF and cyclin D2 expression in primary colorectal carcinomas.
Diagn Mol Pathol. 19:194–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang Y, Yao L, Zhang X, Ji H, Wang L, Sun
S and Pang D: Elevated expression of USP22 in correlation with poor
prognosis in patients with invasive breast cancer. J Cancer Res
Clin Oncol. 137:1245–1253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang XY, Pfeiffer HK, Thorne AW and
McMahon SB: USP22, an hSAGA subunit and potential cancer stem cell
marker, reverses the polycomb-catalyzed ubiquitylation of histone
H2A. Cell Cycle. 7:1522–1524. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Atanassov BS and Dent SY: USP22 regulates
cell proliferation by deubiquitinating the transcriptional
regulator FBP1. EMBO Rep. 12:924–930. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tang B, Du J, Wang J, Tan G, Gao Z, Wang Z
and Wang L: Alpinetin suppresses proliferation of human hepatoma
cells by the activation of MKK7 and elevates sensitization to
cis-diammined dichloridoplatium. Oncol Rep. 27:1090–1096. 2012.
|
|
17
|
Glinsky GV, Berezovska O and Glinskii AB:
Microarray analysis identifies a death-from-cancer signature
predicting therapy failure in patients with multiple types of
cancer. J Clin Invest. 115:1503–1521. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu YL, Yang YM, Xu H and Dong XS:
Aberrant expression of USP22 is associated with liver metastasis
and poor prognosis of colorectal cancer. J Surg Oncol. 103:283–289.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu YL, Jiang SX, Yang YM, Xu H, Liu JL
and Wang XS: USP22 acts as an oncogene by the activation of
BMI-1-mediated INK4a/ARF pathway and Akt pathway. Cell Biochem
Biophys. 62:229–235. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lv L, Xiao XY, Gu ZH, Zeng FQ, Huang LQ
and Jiang GS: Silencing USP22 by asymmetric structure of
interfering RNA inhibits proliferation and induces cell cycle
arrest in bladder cancer cells. Mol Cell Biochem. 346:11–21. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu H, Liu YL, Yang YM and Dong XS:
Knock-down of ubiquitin-specific protease 22 by micro-RNA
interference inhibits colorectal cancer growth. Int J Colorectal
Dis. 27:21–30. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu J, Liu YL, Piao SL, Yang DD, Yang YM
and Cai L: Expression patterns of USP22 and potential targets
BMI-1, PTEN, p-AKT in non-small-cell lung cancer. Lung Cancer.
77:593–599. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nicholson DW, Ali A, Thornberry NA,
Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle
M and Lazebnik YA: Identification and inhibition of the ICE/CED-3
protease necessary for mammalian apoptosis. Nature. 376:37–43.
1995. View
Article : Google Scholar : PubMed/NCBI
|
